clinical trial · NCT05647811
Study of NM8074 in Adult C3 Glomerulopathy Patients
C3 GlomerulopathyNM8074
brief summary
This is a Phase Ib, open-label, dose-escalation study designed to evaluate the safety, efficacy, and immunogenicity of NM8074 administered intravenously to patients with C3 Glomerulopathy.
started
May 1, 2027
primary completion
Aug 1, 2029
completion
Jul 1, 2030
last updated
Apr 13, 2026
detailed description
The proposed study, NM8074-C3G-101, will enroll a planned number of 18 patients, with the potential to enroll more patients. There will be 3 cohorts with 6 patients each dosed at 5, 10, or 20 mg/kg depending on which cohort they are assigned to. Enrollment in the subsequent higher dose level cohort will occur after the previous cohort has been evaluated for safety.
official title
A Phase Ib, Open Label, Dose Escalation Study of NM8074 in Subjects With C3 Glomerulopathy (C3G)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol